Results 31 to 40 of about 31,135 (223)
LRRC8A promotes the initial development of oxaliplatin resistance in colon cancer cells
Heliyon, 2023 Leucine-rich repeat-containing 8 A (LRRC8A) is an essential component of the volume-regulated anion channel (VRAC), which plays a vital role in cell proliferation, migration, apoptosis, and drug resistance.
Haifeng Zhang +9 more
doaj +1 more source
Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer
Cancers, 2022 Resistance to treatments is one of the leading causes of cancer therapy failure. Oxaliplatin is a standard chemotherapy used to treat metastatic colorectal cancer. However, its efficacy is greatly reduced by the development of resistances. In a previous study, we deciphered the mechanisms leading to oxaliplatin resistance and highlighted the roles ...
Chocry, Mathieu +5 more
openaire +2 more sources
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review [PDF]
Cancer Treatment Reviews, 2007 Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with "cisplatin-resistant" cancer.
Stordal, Britta +2 more
openaire +5 more sources
Signal Transduction and Targeted Therapy, 2022 Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an estimated 50% of patients will eventually stop responding to treatment due to acquired resistance.
Yimin Li +14 more
doaj +1 more source
The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer [PDF]
Frontiers in Molecular Biosciences, 2021 BackgroundColorectal cancer (CRC) is estimated to be one of the most common cancers and the leading cause of cancer-related death worldwide. SOX9 is commonly overexpressed in CRC and participates in drug resistance. In addition, DNA damage repair confers resistance to anticancer drugs.
Yiqiang Liu +13 more
openaire +3 more sources
MedComm, 2023 Oxaliplatin is commonly used as the first‐line chemotherapeutic agent for advanced hepatocellular carcinoma (HCC). Unfortunately, the acquired resistance, limits the effectiveness of oxaliplatin and the underlying mechanisms remain unknown. Therefore, we
Wenfeng Liu +6 more
doaj +1 more source
WBSCR22 confers oxaliplatin resistance in human colorectal cancer [PDF]
Scientific Reports, 2017 AbstractHuman WBSCR22 gene is involved in tumor metastasis, cell growth and invasion, however, its role in chemosensitivity to antitumor agents remains unknown. In this study, we analyzed the TCGA cohort and found the expression of WBSCR22 was significantly elevated in human colorectal cancer (CRC) tissue. WBSCR22 could be served as an independent risk
Yan, Dongmei +6 more
openaire +2 more sources
BMC Cancer, 2020 Background Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses.
Xia Liao +9 more
doaj +1 more source
Frontiers in Oncology, 2021 Numerous colon cancer cases are resistant to chemotherapy based on oxaliplatin and suffer from relapse. A number of survival- and prognosis-related biomarkers have been identified based on database mining for patients who develop drug resistance, but the
Qiu Lin, Li Luo, Hua Wang
doaj +1 more source
Cell Death and Disease, 2021 Long noncoding RNAs (lncRNAs) have emerged as a new class of regulatory molecules implicated in therapeutic resistance, yet the mechanisms underlying lncRNA-mediated oxaliplatin resistance in colorectal cancer (CRC) are poorly understood.
Xuan Deng +11 more
doaj +1 more source